Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Angela Humphrey is active.

Publication


Featured researches published by Angela Humphrey.


Jacc-cardiovascular Interventions | 2009

Outcomes With Drug-Eluting Versus Bare-Metal Stents in Saphenous Vein Graft Intervention: Results From the STENT (Strategic Transcatheter Evaluation of New Therapies) Group

Bruce R. Brodie; Hadley Wilson; Thomas Stuckey; Marcy Nussbaum; Sherry Laurent; Barbara Bradshaw; Angela Humphrey; Chris Metzger; James B. Hermiller; Fred Krainin; Stanley Juk; Barry Cheek; Peter L. Duffy; Charles A. Simonton

OBJECTIVES This study compares outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients undergoing saphenous vein graft (SVG) intervention. BACKGROUND The safety and efficacy of DES in patients undergoing SVG intervention is controversial. METHODS The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is a multicenter U.S. registry evaluating outcomes with DES. Our study population includes patients undergoing PCI of SVG lesions with DES (n = 785) or BMS (n = 343) who completed 9-month or 2-year follow-up. Outcomes were adjusted with propensity analyses. RESULTS The DES patients had fewer emergent procedures but had smaller vessels and longer lesions. The DES patients had less death or myocardial infarction at 9 months (hazard ratio [HR]: 0.52, 95% confidence interval [CI]: 0.33 to 0.83, p = 0.006) and less death at 2 years (HR: 0.60, 95% CI: 0.36 to 0.98, p = 0.041). Target vessel revascularization (TVR) was less with DES at 9 months (7.2% vs. 10.0%, HR: 0.36, 95% CI: 0.22 to 0.61, p < 0.001) but was no different by 2 years (18.3% vs. 16.9%, p = 0.86), although adjusted TVR rates were lower (HR: 0.60, 95% CI: 0.40 to 0.90, p = 0.014). The DES reduced TVR at 9 months in SVG lesions with diameter <3.5 mm (8.0% vs. 17.2%, p = 0.013) but not >or=3.5 mm (6.0% vs. 6.6%, p = 0.74). CONCLUSIONS Treatment of SVG lesions with DES vs. BMS is effective in reducing TVR at 9 months, although most of this advantage is lost at 2 years. The DES seem safe with less death or myocardial infarction, although selection bias might have affected these results. Our data suggest that DES might have short-term advantages over BMS in SVG lesions with diameter <3.5 mm.


Catheterization and Cardiovascular Interventions | 2008

Outcomes with drug-eluting stents versus bare metal stents in acute ST-elevation myocardial infarction: Results from the Strategic Transcatheter Evaluation of New Therapies (STENT) Group†

Bruce R. Brodie; Thomas Stuckey; William Downey; Angela Humphrey; Marcy Nussbaum; Sherry Laurent; Barbara Bradshaw; Chris Metzger; James B. Hermiller; Fred Krainin; Stanley Juk; Barry Cheek; Peter L. Duffy; Charles A. Simonton

This study compares outcomes with drug‐eluting stents (DES) versus bare metal stents (BMS) in patients with ST‐elevation myocardial infarction (STEMI).


Eurointervention | 2011

An integer based risk score for predicting 30-day major adverse cardiac or cerebrovascular events after percutaneous coronary intervention with drug-eluting stents: results from a large prospective multicentre registry, the STENT Group

Hiroki Ito; Marcy Nussbaum; James B. Hermiller; Zachary Hodes; Bruce R. Brodie; Barrett Cheek; Stanley Juk; Fred Krainin; Christopher Metzger; Peter L. Duffy; Angela Humphrey; Sherry Laurent; Charles A. Simonton

AIMS Previous risk models predicting in-hospital major adverse cardiac or cerebrovascular events (MACCE) after percutaneous coronary interventions (PCI) may underestimate actual short-term post-procedure complications due to the trend toward early discharge of patients. METHODS AND RESULTS Using a subset (N=10,679) from the STENT Group registry, a logistic regression model was developed to predict 30-day MACCE which includes death, myocardial infarction, target vessel revascularisation and stroke. An integer-based risk score was created from the model and validated in another subset (N=3,099). In the study subset, there was significant difference between in-hospital and 30-day MACCE N=443 (2.0%) vs. 131 (4.2), p<0.01, respectively. A final risk model included nine variables; absence of pre-procedural statin (odds ratio=1.3, 95% confidence interval=1.0-1.5), haemoglobin level (0.9/1 gm increase, 0.8-0.9), cardiogenic shock (4.4, 3.1-6.3), acute congestive heart failure (1.6, 1.2-2.3), left main disease (2.2, 1.3-3.7), left anterior descending artery lesion (1.3, 1.0-1.5), ostial lesion (1.6, 1.2-2.1), coronary thrombosis (2.0, 1.4-2.9) and ACC/AHA type C lesion (1.3, 1.1-1.6). The c-statistics of the final model were 0.653 and 0.692 in the study and validation subset, respectively. CONCLUSIONS In this large real world registry of DES, in-hospital MACCE did not represent short-term post-procedure prognosis. The risk model consisting of nine variables predicted 30-day MACCE with modest discriminatory value.


American Journal of Obstetrics and Gynecology | 2001

A randomized controlled trial comparing oxytocin administration before and after placental delivery in the prevention of postpartum hemorrhage

Kenneth W. Jackson; John R. Allbert; Glenn K. Schemmer; Mollie Elliot; Angela Humphrey; Jane Taylor


Jacc-cardiovascular Interventions | 2008

Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.

Bruce R. Brodie; Thomas Stuckey; William Downey; Angela Humphrey; Barbara Bradshaw; Chris Metzger; James B. Hermiller; Fred Krainin; Stanley Juk; Barry Cheek; Peter L. Duffy; Henry Smith; John Edmunds; Jay Varanasi; Charles A. Simonton


Journal of the American College of Cardiology | 2007

Comparative clinical outcomes of paclitaxel-and sirolimus-eluting stents : Results from a large prospective multicenter registry-STENT group

Charles A. Simonton; Bruce R. Brodie; Barrett Cheek; Fred Krainin; Chris Metzger; James B. Hermiller; Stanley Juk; Peter L. Duffy; Angela Humphrey; Marcy Nussbaum; Sherry Laurent


Jacc-cardiovascular Interventions | 2014

Reply: Is D2B the Only Metric to Determine Outcome With STEMI?

B. Hadley Wilson; Angela Humphrey; J. Lee Garvey


Journal of the American College of Cardiology | 2012

INITIAL AMBULANCE TRANSPORT OF ST-ELEVATION MYOCARDIAL INFARCTION (STEMI) TO RURAL HOSPITALS LEADS TO BETTER DOOR IN-DOOR OUT AND FIRST DOOR TO BALLOON REPERFUSION TIMES WITHIN 90 MINUTES

B. Hadley Wilson; Angela Humphrey; Robert Haber; William E. Downey; John C. Cedarholm; Glen J. Kowalchuk; Michael J. Rinaldi; Denise A. Miller; Jennifer L. Sarafin; Kevin M. Collier; J. Garvey


Journal of the American College of Cardiology | 2011

AIR TRANSPORTS IN THE AGE OF STEMI SYSTEM REGIONALIZATION

B. Hadley Wilson; Angela Humphrey; Robert Haber; William E. Downey; John C. Cedarholm; Glen J. Kowalchuk; Michael J. Rinaldi; Kevin M. Collier; Patricia M. Pye; Denise A. Miller; Jennifer L. Sarafin; Mason Ellerbe; J. Lee Garvey


Archive | 2010

Results From a Large Prospective Multicenter RegistrySTENT Group Comparative Clinical Outcomes of Paclitaxel- and Sirolimus-Eluting Stents:

James B. Hermiller; Stanley Juk; Peter J. Duffy; Angela Humphrey; Marcy Nussbaum; Charles A. Simonton; Bruce Brodie; Barrett Cheek; Fred Krainin; Christopher Metzger

Collaboration


Dive into the Angela Humphrey's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

James B. Hermiller

St. Vincent's Health System

View shared research outputs
Top Co-Authors

Avatar

Marcy Nussbaum

Carolinas Medical Center

View shared research outputs
Top Co-Authors

Avatar

Peter L. Duffy

Cedars-Sinai Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sherry Laurent

Carolinas Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

J. Lee Garvey

Carolinas Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge